Acumen Pharmaceuticals (NASDAQ:ABOS) CFO Matt Zuga Sells 5,805 Shares

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) CFO Matt Zuga sold 5,805 shares of the firm’s stock in a transaction that occurred on Wednesday, January 7th. The shares were sold at an average price of $1.99, for a total transaction of $11,551.95. Following the completion of the sale, the chief financial officer directly owned 216,839 shares of the company’s stock, valued at approximately $431,509.61. This represents a 2.61% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Matt Zuga also recently made the following trade(s):

• On Tuesday, January 6th, Matt Zuga sold 5,100 shares of Acumen Pharmaceuticals stock. The shares were sold at an average price of $1.97, for a total value of $10,047.00.
• On Monday, January 5th, Matt Zuga sold 4,000 shares of Acumen Pharmaceuticals stock. The shares were sold at an average price of $1.96, for a total value of $7,840.00.

Acumen Pharmaceuticals Trading Up 1.5%

Shares of ABOS traded up $0.03 during trading hours on Wednesday, hitting $1.99. 220,171 shares of the stock traded hands, compared to its average volume of 159,170. The business has a fifty day moving average of $1.96 and a 200-day moving average of $1.67. The firm has a market capitalization of $120.53 million, a PE ratio of -0.90 and a beta of 0.23. Acumen Pharmaceuticals, Inc. has a 1-year low of $0.86 and a 1-year high of $2.46. The company has a current ratio of 6.02, a quick ratio of 6.02 and a debt-to-equity ratio of 0.29.

Acumen Pharmaceuticals (NASDAQ:ABOS) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.44) earnings per share for the quarter, topping the consensus estimate of ($0.63) by $0.19. Analysts expect that Acumen Pharmaceuticals, Inc. will post -1.56 EPS for the current year.

Institutional Investors Weigh In On Acumen Pharmaceuticals

Several hedge funds have recently bought and sold shares of the company. Invesco Ltd. boosted its position in shares of Acumen Pharmaceuticals by 544.1% during the first quarter. Invesco Ltd. now owns 127,798 shares of the company’s stock worth $141,000 after purchasing an additional 107,956 shares in the last quarter. AQR Capital Management LLC acquired a new stake in Acumen Pharmaceuticals during the 1st quarter worth $46,000. Y Intercept Hong Kong Ltd acquired a new stake in Acumen Pharmaceuticals during the 2nd quarter worth $291,000. Marshall Wace LLP bought a new position in Acumen Pharmaceuticals during the second quarter worth about $160,000. Finally, Qube Research & Technologies Ltd grew its stake in Acumen Pharmaceuticals by 160.0% in the second quarter. Qube Research & Technologies Ltd now owns 57,559 shares of the company’s stock valued at $67,000 after acquiring an additional 35,424 shares during the period. 71.01% of the stock is currently owned by institutional investors and hedge funds.

More Acumen Pharmaceuticals News

Here are the key news stories impacting Acumen Pharmaceuticals this week:

• Neutral Sentiment: No stated reason in filings — The disclosures show routine Form 4 sales but do not explain whether trades were pre‑planned or for personal liquidity/diversification; that ambiguity leaves market interpretation open.
• Negative Sentiment: CEO Daniel Joseph O’Connell sold a total of 47,506 shares across Jan. 5–7 (individual trades of 4,649; 5,102; and 37,755 shares), receiving about $94.3k in proceeds; the largest single trade (37,755 shares) was reported as a 5.74% reduction in his stake. Read More.
• Negative Sentiment: CFO Matt Zuga sold 14,905 shares over Jan. 5–7 (4,000; 5,100; 5,805), totaling roughly $29.4k in proceeds and small single‑trade ownership reductions (1.73%–2.61%). Read More.
• Negative Sentiment: COO Russell Barton sold 9,318 shares over Jan. 5–7 (4,000; 3,618; 1,700), raising about $18.4k and reducing his stake by small single‑trade percentages (1.32%–2.94%). Read More.
• Negative Sentiment: Insider Eric Siemers sold 10,834 shares on Jan. 5–6 (4,000; 6,834), for about $21.3k in proceeds and reported ownership reductions of ~2.35%–4.11% per trade. Read More.

Analysts Set New Price Targets

A number of equities analysts have issued reports on ABOS shares. Wall Street Zen raised shares of Acumen Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Sunday, December 21st. Bank of America cut their price target on Acumen Pharmaceuticals from $9.00 to $8.00 and set a “buy” rating on the stock in a research note on Tuesday, November 18th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Acumen Pharmaceuticals in a research note on Tuesday, October 14th. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $6.75.

About Acumen Pharmaceuticals

Acumen Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral small molecule therapies for neurodegenerative diseases. Leveraging a proprietary drug discovery platform that integrates chemoproteomics, high-throughput screening and computational chemistry, the company seeks to identify and optimize compounds that selectively modulate pathological protein aggregation. Its approach is designed to address the underlying biology of conditions such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis and related proteinopathies.

The company’s pipeline comprises multiple lead candidates at various stages of preclinical and early clinical development.